Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.46
  • Today's Change0.032 / 0.93%
  • Shares traded60.50k
  • 1 Year change+17.95%
  • Beta1.1658
Data delayed at least 15 minutes, as of Dec 02 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

  • Revenue in EUR (TTM)94.34m
  • Net income in EUR47.80m
  • Incorporated1999
  • Employees134.00
  • Location
    Genfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
  • Phone+33 320164000
  • Fax+33 320164001
  • Websitehttps://www.genfit.fr/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GNFT:PAR since
Versantis AGDeal completed19 Sep 202219 Sep 2022Deal completed-14.46%108.85m
Data delayed at least 15 minutes, as of Dec 02 2022 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Pcas SA190.57m-67.46m108.41m1.18k------0.5689-4.91-4.9113.87-0.07340.62981.765.76162,738.70-22.29-4.98-63.25-8.4929.9041.29-35.40-6.530.3374-15.391.01---3.66-0.5247-170.81--12.84--
Eurofins-Cerep SA41.62m9.84m111.98m197.0011.382.4710.032.691,951.381,951.388,257.309,003.020.78682.416.40211,252.7018.6114.1523.2117.7786.2959.0123.6517.723.7013.880.0623--27.4012.1776.4831.68----
Aelis Farma SA3.14m-13.56m122.14m24.00--5.11--38.85-1.19-1.190.26691.910.0824--1.34131,000.00-35.51---55.15-------431.23--2.85-0.96170.0794------127.52------
Ose Immunotherapeutics SA33.38m-7.34m132.29m60.00--2.82--3.96-0.3998-0.39981.812.530.333--58.56547,180.30-7.32-9.88-9.23-11.76-----21.99-45.90---6.620.4332--152.17133.01-1.78--73.53--
Nanobiotix SA0.00-42.94m135.12m103.00--75.46-----1.23-,902.42----0.9593---80.00-63.57-39.93------
Biosynex SA299.54m64.10m148.66m328.002.530.84132.030.49635.735.7326.6817.241.182.6321.281,105,327.0027.3434.5937.5046.9447.9551.6723.1522.283.41760.560.171516.36148.5769.88231.54------
AFYREN SA3.28m-6.23m151.48m70.00--2.03--46.23-0.3152-0.31520.16712.900.0532--7.6746,814.29-10.11---11.41--94.35---190.05-----1.670.1033---23.93---69.20------
Abivax SA0.00-54.38m155.30m24.00---------3.08-3.080.00-0.04480.00----0.00-85.81-43.17-167.65-61.15-----------27.481.02-------10.14---42.08--
Medincell SA4.09m-24.81m158.46m156.00------38.74-0.9975-0.99750.1645-0.53250.07587.506.3926,217.95-45.98-51.57-88.49-74.5863.2375.62-606.50-421.410.8844-25.201.44---50.04---30.65------
Gensight Biologics SA2.76m-31.03m164.49m44.00--51.36--59.51-0.6755-0.67550.06040.06910.0512--2.2272,736.84-57.52-63.75-87.71-83.23-----1,122.58-1,456.76----0.834--20.07--15.87---29.91--
Genfit SA94.34m47.80m172.23m134.005.301.583.431.830.65240.65241.612.190.5089485.25145.25842,312.5025.79-18.6731.40-21.8297.9493.3950.67-157.666.33--0.3957--1,003.1166.03166.45---23.40--
Inventiva SA4.12m-55.97m175.28m109.00--2.51--42.52-1.39-1.390.10241.650.0365--1,030.5041,220.00-49.61-38.16-59.96-45.17-----1,357.74-849.654.14--0.21--1,027.42-14.99-47.64--18.56--
Innate Pharma SA45.08m-15.38m178.87m213.00--1.53--3.97-0.1914-0.28370.56371.460.1649--8.99209,669.80-5.63-6.65-7.15-9.5893.7192.81-34.12-45.00----0.5004---78.43-26.42-5,385.89---32.35--
Transgene SA18.12m-23.02m188.78m165.00--3.47--10.42-0.2337-0.23370.18420.54290.1881--6.55108,473.10-23.89-15.27-27.55-18.27-----127.05-147.28----0.0556--82.1014.28-13.38--90.14--
Guerbet SA740.03m12.59m217.43m2.73k17.360.50603.070.29380.99080.990858.0933.990.7530.86125.65271,072.901.283.621.675.0473.7975.551.704.701.039.860.420827.452.78-1.1578.932.44-0.34430.00
Eurobio Scientific SA172.74m46.71m223.69m165.004.391.333.981.294.504.5016.6414.880.87775.034.471,046,885.0023.7324.1328.5034.4651.0550.5227.0423.664.58--0.07630.00-2.1946.13-17.61--55.99--
Data as of Dec 02 2022. Currency figures normalised to Genfit SA's reporting currency: Euro EUR

Institutional shareholders

2.09%Per cent of shares held by top holders
HolderShares% Held
Healthinvest Partners ABas of 30 Jun 2022325.00k0.65%
Goldman Sachs Asset Management Internationalas of 30 Sep 2022306.68k0.62%
American Century Investment Management, Inc.as of 03 Nov 202275.67k0.15%
Sunny Asset Management SAas of 27 Oct 202270.00k0.14%
Mandarine Gestion SAas of 29 Jul 202263.00k0.13%
Norges Bank Investment Managementas of 31 Dec 202155.62k0.11%
PKB PRIVATBANK SAas of 25 Sep 202050.00k0.10%
Dimensional Fund Advisors LPas of 03 Nov 202248.19k0.10%
Abeille Asset Management SAas of 31 Dec 201931.13k0.06%
Bessemer Investment Management LLCas of 29 Jul 202216.18k0.03%
More ▼
Data from 31 Dec 2021 - 24 Nov 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.